Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Cancers|July 2, 2021
Drug Development in Tissue-Agnostic IndicationsPauline du Rusquec, Christophe Le Tourneau
Oncoimmunology|September 16, 2020
Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid TumorsMarion Alcantara, Pauline Du Rusquec, Emanuela Romano
Therapeutic Advances in Medical Oncology|August 13, 2020
Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancerPauline du Rusquec, Cyriac Blonz, Jean Sebastien Frenel, et al.
Cancer Management and Research|June 14, 2019
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new dataPauline du Rusquec, Ombline de Calbiac, Marie Robert, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 13, 2020
Pseudoprogression and Hyperprogression as New Forms of Response to ImmunotherapyMaxime Frelaut, Pauline du Rusquec, Alexandre de Moura, et al.
Eclinicalmedicine|November 8, 2021
Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysisCamille Moreau Bachelard, Elodie Coquan, Pauline du Rusquec, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 10, 2014
Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanomaPauline du Rusquec, Melanie Saint-Jean, Anabelle Brocard, et al.
Bulletin Du Cancer|November 27, 2025
[Upper-gastrointestinal tract toxicities associated with Immune Checkpoint Inhibitors (ICI)]Justine Vivier Chicoteau, Lucie Thibault, Pauline Vaflard, et al.
Cancers|August 10, 2024
Real-World Survival Impact of New Treatment Strategies for Lung Cancer: A 2000-2020 French CohortClemence Basse, Matthieu Carton, Maud Milder, et al.
Respiratory Medicine and Research|February 21, 2026
Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progressionPaul Lajoinie, Vincent Fallet, Marie Wislez, et al.
Pageof 3